Results of surgical intervention for p-stage IIIA (N2) non–small cell lung cancer: Acceptable prognosis predicted by complete resection in patients with.

Slides:

Advertisements

Similar presentations

Stephen R. Broderick, MD, MPHS

Advertisements

The eighth edition TNM stage classification for lung cancer: What does it mean on main street? Frank C. Detterbeck, MD The Journal of Thoracic and Cardiovascular.

Synchronous multiple primary lung cancer: An increasing clinical occurrence requiring multidisciplinary management Delphine Trousse, MD, Fabrice Barlesi,

Michael Y. Chang, MD, MPH, Steven J. Mentzer, MD, Yolonda L

Characteristics and outcomes of secondary nodules identified on initial computed tomography scan for patients undergoing resection for primary non–small.

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Cytologically malignant margins of wedge resected stage I non-small cell lung cancer Noriyoshi Sawabata, MD, Akihide Matsumura, MD, Mitsunori Ohota, MD,

Malignant minor pleural effusion detected on thoracotomy for patients with non–small cell lung cancer: is tumor resection beneficial for prognosis? Noriyoshi.

Effect of tumor size on prognosis in patients with non–small cell lung cancer: The role of segmentectomy as a type of lesser resection Morihito Okada,

Prognostic significance of histologic differentiation, carcinoembryonic antigen value, and lymphovascular invasion in stage I non–small cell lung cancer

Paul J. Scheel, BS, Traves D. Crabtree, MD, Jennifer M

Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system Shamus R.

Prognostic evaluation based on a new TNM staging system proposed by the International Association for the Study of Lung Cancer for resected non–small.

Radical sublobar resection for small-sized non–small cell lung cancer: A multicenter study Morihito Okada, MD, PhD, Teruaki Koike, MD, PhD, Masahiko.

The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer Kyong-Ah Yoon,

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer Hong.

Detection of circulating tumor cells in patients with non–small cell lung cancer undergoing lobectomy by video-assisted thoracic surgery: A potential.

Survival after resection of synchronous non–small cell lung cancer

Patient-Reported Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer Frank J. Lagerwaard, MD, PhD, Neil K. Aaronson,

Surgical treatment of metachronous second primary lung cancer after complete resection of non–small cell lung cancer Masatsugu Hamaji, MD, Mark S. Allen,

The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao,

Sleeve lung resection for lung cancer: Analysis according to the type of procedure Kazumichi Yamamoto, MD, Yoshihiro Miyamoto, MD, Akihiro Ohsumi, MD,

Survival related to lymph node involvement in lung cancer after sleeve lobectomy compared with pneumonectomy Morihito Okada, MD, Hiroyuki Yamagishi,

John M. Varlotto, MD, Abram Recht, MD, John C. Flickinger, MD, Laura N

Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non–small-cell lung cancer Walter Weder, MD, Stéphane Collaud, MD,

Benefits of resection for metachronous lung cancer

Patterns of survival and recurrence after surgical treatment of early stage non–small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial Stacey.

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer Registry Bing-Yen Wang, MD, Jing-Yang Huang, Ching-Yuan Cheng, MD, Ching-Hsiung Lin, MD,

Elizabeth A. David, MD, MAS, Stina W. Andersen, PhD, Laurel A

Treatment trends in early-stage lung cancer in the United States, 2004 to 2013: A time- trend analysis of the National Cancer Data Base Kathryn E. Engelhardt,

A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non–small cell lung cancer Christopher.

Segmentectomy for selected cT1N0M0 non–small cell lung cancer: A prospective study at a single institute Hiroaki Nomori, PhD, Takeshi Mori, PhD, Koei.

Yang Zhang, MD, Haiquan Chen, MD, PhD

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Management of stage IIIA (N2) non–small cell lung cancer: A transatlantic perspective Gaetano Rocco, MD, Katie Nason, MD, MPH, Alex Brunelli, MD, Gonzalo.

Prolonged survival in patients with resected non–small cell lung cancer and single-level N2 disease Steven M Keller, MD, Mark G Vangel, PhD, Henry Wagner,

Is surgery for multiple lung metastases reasonable

Stephen R. Broderick, MD, MPHS

Surgery for aortic and mitral valve disease in the United States: A trend of change in surgical practice between 1998 and 2005 Scott D. Barnett, PhD,

Resection of primary lung cancer with incidental pleural seeding: Seeds of change or reap what you sow? Jules Lin, MD The Journal of Thoracic and Cardiovascular.

The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: Implications for revision of the.

Adjuvant Surgery after Carboplatin and VP16 in Resectable Small Cell Lung Cancer Giulia Veronesi, MD, Paolo Scanagatta, MD, Francesco Leo, MD, Tommaso.

Video-assisted resection for lung cancer results in fewer complications Lunxu Liu, PhD, MD, FRCS The Journal of Thoracic and Cardiovascular Surgery

Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: The Japan Clinical.

Video-assisted mediastinoscopic lymphadenectomy is associated with better survival than mediastinoscopy in patients with resected non–small cell lung.

Benefits of surgery for patients with pulmonary metastases from colorectal carcinoma Masayoshi Inoue, MD, Mitsunori Ohta, MD, Keiji Iuchi, MD, Akihide.

Development of a patient-centered aggregate score to predict survival after lung resection for non–small cell lung cancer Alessandro Brunelli, MD, Michele.

Percutaneous radiofrequency ablation of clinical stage I non–small cell lung cancer Takao Hiraki, MD, Hideo Gobara, MD, Hidefumi Mimura, MD, Yusuke Matsui,

Risk of Pleural Recurrence After Computed Tomographic-Guided Percutaneous Needle Biopsy in Stage I Lung Cancer Patients Masayoshi Inoue, MD, PhD, Osamu.

Optimal distance of malignant negative margin in excision of nonsmall cell lung cancer: a multicenter prospective study Noriyoshi Sawabata, MD, Mitsunori.

Multifocal lung cancer within ground glass lesions: Are favorable outcomes consequent to surgical resection or inherent to the disease? Mara B. Antonoff,

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

Stage III thymoma: Relationship of local invasion to recurrence

The future of cardiac surgery training: A survival guide

Linda W. Martin, MD, MPH, FCCP, FACS, Gail E

Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer Steven M Keller, MD, Sudeshna Adak,

Aritoshi Hattori, MD, Kenji Suzuki, MD

Salvage surgery for advanced non–small cell lung cancer after response to gefitinib Tomoyuki Hishida, MD, Kanji Nagai, MD, Tetsuya Mitsudomi, MD, Kohei.

Who should decide margin length in pulmonary excision of lung cancer?

Is there a benefit to continuing with resection of all sites of disease when clinically occult pleural metastases from non–small cell carcinoma are found?

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

Population-Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013 Chris Dickhoff, MD, Max Dahele, MBChB., PhD,

Prognostic impact of large cell neuroendocrine histology in patients with pathologic stage Ia pulmonary non–small cell carcinoma Akira Iyoda, MD, Kenzo.

Reappraise the advanced technique for tumor localization and sentinel lymph node assessment in clinical early-stage non–small cell lung cancer Chengwu.

Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey.

Kristin A. Higgins, MD, Junzo P. Chino, MD, Neal Ready, MD, Mark W

Presentation transcript:

Results of surgical intervention for p-stage IIIA (N2) non–small cell lung cancer: Acceptable prognosis predicted by complete resection in patients with single N2 disease with primary tumor in the upper lobe Masayoshi Inoue, MD, PhD, Noriyoshi Sawabata, MD, PhD, Shin-ichi Takeda, MD, PhD, Mitsunori Ohta, MD, PhD, Yuko Ohno, PhD, Hajime Maeda, MD, PhD The Journal of Thoracic and Cardiovascular Surgery Volume 127, Issue 4, Pages 1100-1106 (April 2004) DOI: 10.1016/j.jtcvs.2003.09.012

Figure 1 Overall survival for 154 patients with p-stage IIIA (N2) NSCLC who underwent a complete resection. The Journal of Thoracic and Cardiovascular Surgery 2004 127, 1100-1106DOI: (10.1016/j.jtcvs.2003.09.012)

Figure 2 Probability of survival for patients with stage IIIA (N2) NSCLC who underwent a complete resection according to N2 level. Survival for those with single N2 disease was significantly better than for those with multiple N2 disease. The Journal of Thoracic and Cardiovascular Surgery 2004 127, 1100-1106DOI: (10.1016/j.jtcvs.2003.09.012)

Figure 3 Probability of survival for patients with stage IIIA (N2) NSCLC who underwent a complete resection according to primary tumor location. Two patients with a tumor in the left main bronchus were excluded from these results. Patients with a tumor in the upper lobe showed a significantly longer survival compared with that in those with a tumor in the middle-lower lobe. The Journal of Thoracic and Cardiovascular Surgery 2004 127, 1100-1106DOI: (10.1016/j.jtcvs.2003.09.012)

Figure 4 Probability of survival for patients with stage IIIA (N2) NSCLC who underwent a complete resection according to both N2 level and tumor location. Two patients with a tumor in the left main bronchus were excluded from these results. The survival of patients with single N2 disease and upper lobe primary involvement was significantly better compared with that of those with multiple N2 disease and upper lobe primary involvement (P = .0010) or those with multiple N2 disease and middle-lower lobe primary involvement (P < .0001) and also tended to be better than survival in patients with single N2 disease and middle-lower lobe primary involvement (P = .0900). The Journal of Thoracic and Cardiovascular Surgery 2004 127, 1100-1106DOI: (10.1016/j.jtcvs.2003.09.012)

The Journal of Thoracic and Cardiovascular Surgery 2004 127, 1100-1106DOI: (10.1016/j.jtcvs.2003.09.012)